Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Wei Yee Chan; Nicholas Counsell; Ruth de Tute; Dunnya De‐Silva; Elizabeth H. Phillips; Jamie Cavenagh; Toyin Adedayo; Nivette Braganca; Claire Roddie; Matthew Streetly; Stephen Schey; Mickey B.C. Koh; Josephine Crowe; Treen C. Morris; Gordon Cook; Laura Clifton‐Hadley; Neil Rabin; Roger G. Owen; Rakesh Popat; Kwee L. Yong

doi:10.1111/bjh.17903

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Wei Yee Chan, Nicholas Counsell, Ruth de Tute, Dunnya De‐Silva, Elizabeth H. Phillips, Jamie Cavenagh, Toyin Adedayo, Nivette Braganca, Claire Roddie, Matthew Streetly, Stephen Schey, Mickey B.C. Koh, Josephine Crowe, Treen C. Morris, Gordon Cook, Laura Clifton‐Hadley, Neil Rabin, Roger G. Owen, Rakesh Popat, Kwee L. Yong

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.17903
Publication status	Published - Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.17903

Cite this

Chan, W. Y., Counsell, N., de Tute, R., De‐Silva, D., Phillips, E. H., Cavenagh, J., Adedayo, T., Braganca, N., Roddie, C., Streetly, M., Schey, S., Koh, M. B. C., Crowe, J., Morris, T. C., Cook, G., Clifton‐Hadley, L., Rabin, N., Owen, R. G., Popat, R., & Yong, K. L. (2022). Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology. https://doi.org/10.1111/bjh.17903

@article{407c057927c84de494a1e9c5bb46d5dd,

title = "Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial",

author = "Chan, {Wei Yee} and Nicholas Counsell and {de Tute}, Ruth and Dunnya De‐Silva and Phillips, {Elizabeth H.} and Jamie Cavenagh and Toyin Adedayo and Nivette Braganca and Claire Roddie and Matthew Streetly and Stephen Schey and Koh, {Mickey B.C.} and Josephine Crowe and Morris, {Treen C.} and Gordon Cook and Laura Clifton‐Hadley and Neil Rabin and Owen, {Roger G.} and Rakesh Popat and Yong, {Kwee L.}",

year = "2022",

month = feb,

doi = "10.1111/bjh.17903",

language = "Undefined",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Ltd",

}

Chan, WY, Counsell, N, de Tute, R, De‐Silva, D, Phillips, EH, Cavenagh, J, Adedayo, T, Braganca, N, Roddie, C, Streetly, M, Schey, S, Koh, MBC, Crowe, J, Morris, TC, Cook, G, Clifton‐Hadley, L, Rabin, N, Owen, RG, Popat, R & Yong, KL 2022, 'Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial', British Journal of Haematology. https://doi.org/10.1111/bjh.17903

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. / Chan, Wei Yee; Counsell, Nicholas; de Tute, Ruth et al.
In: British Journal of Haematology, 02.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

AU - Chan, Wei Yee

AU - Counsell, Nicholas

AU - de Tute, Ruth

AU - De‐Silva, Dunnya

AU - Phillips, Elizabeth H.

AU - Cavenagh, Jamie

AU - Adedayo, Toyin

AU - Braganca, Nivette

AU - Roddie, Claire

AU - Streetly, Matthew

AU - Schey, Stephen

AU - Koh, Mickey B.C.

AU - Crowe, Josephine

AU - Morris, Treen C.

AU - Cook, Gordon

AU - Clifton‐Hadley, Laura

AU - Rabin, Neil

AU - Owen, Roger G.

AU - Popat, Rakesh

AU - Yong, Kwee L.

PY - 2022/2

Y1 - 2022/2

UR - https://doi.org/10.1111/bjh.17903

U2 - 10.1111/bjh.17903

DO - 10.1111/bjh.17903

M3 - Article

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Chan WY, Counsell N, de Tute R, De‐Silva D, Phillips EH, Cavenagh J et al. Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology. 2022 Feb. doi: 10.1111/bjh.17903

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

UN SDGs

Access to Document

Other files and links

Cite this